,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destinybreast04', 'destiny,breast,4', 'breast', 'trastuzumab']
great to see such positive results from #destinybreast04 at #asco22. presumably all down to the improved features of trastuzumab deruxtecan vs. trastuzumab emtansine. illustrations attached! 
Cancer educator | training provider | science communicator | writer | teacher of cancer biology & targeted cancer treatments